RT Journal Article
SR Electronic
T1 Increased plasma heparanase activity in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.12.20129304
DO 10.1101/2020.06.12.20129304
A1 Buijsers, Baranca
A1 Yanginlar, Cansu
A1 Nooijer, Aline de
A1 Grondman, Inge
A1 Maciej-Hulme, Marissa L.
A1 Jonkman, Inge
A1 Janssen, Nico A.F.
A1 Rother, Nils
A1 de Graaf, Mark
A1 Pickkers, Peter
A1 Kox, Matthijs
A1 Joosten, Leo A.B.
A1 Nijenhuis, Tom
A1 Netea, Mihai G.
A1 Hilbrands, Luuk
A1 van de Veerdonk, Frank L.
A1 Duivenvoorden, Raphaël
A1 de Mast, Quirijn
A1 van der Vlag, Johan
YR 2020
UL http://medrxiv.org/content/early/2020/06/21/2020.06.12.20129304.abstract
AB Reports suggest a role of endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize that heparanase contributes to the pathogenesis of COVID-19, and that heparanase may be inhibited by LMWH. Heparanase activity and heparan sulfate levels were measured in plasma of healthy controls (n=10) and COVID-19 patients (n=48).Plasma heparanase activity and heparan sulfate levels were significantly elevated in COVID-19 patients. Heparanase activity associated with disease severity including the need for intensive care and mechanical ventilation, lactate dehydrogenase levels and creatinine levels. Use of prophylactic LMWH in non-ICU patients was associated with a reduced heparanase activity. Since there is no other clinically applied heparanase inhibitor currently available, therapeutic treatment of COVID-19 patients with low molecular weight heparins should be explored.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was performed according to the latest version of the declaration of Helsinki and guidelines for good clinical practice. The local independent ethical committee approved the study protocol (CMO 2020-6344, CMO 2020-6359, CMO 2016-2923).Funding StatementThis study was financially supported by the Radboud university medical center PhD fellow program and consortium grant LSHM16058-SGF (GLYCOTREAT; a collaborative project financed by the PPP allowance made available by Top Sector Life Sciences & Health to the Dutch Kidney Foundation to stimulate public-private partnerships) coordinated by JvdV. MGN was supported by an ERC Advanced grant (#833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed according to the latest version of the declaration of Helsinki and guidelines for good clinical practice. The local independent ethical committee approved the study protocol (CMO 2020-6344, CMO 2020-6359, CMO 2016-2923).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJohan van der Vlag has full access to all the data in the study and takes responsibility for the integrity of the data. All data are available in the manuscript.